Tuesday, November 20, 2018

Ductal carcinoma in situ (DCIS) is non-invasive breast cancer. Ductal means that the cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues (including breast tissue) that cover or line the internal organs, and in situ means "in its original place." DCIS is called "non-invasive" Breast cancer Summit 2019 (17).pngbecause it hasn’t spread beyond the milk duct into any normal surrounding breast tissue. DCIS isn’t life-threatening, but having DCIS can increase the risk of developing an invasive breast cancer later on.
Women who have breast-conserving surgery (lumpectomy) for DCIS without radiation therapy have about a 25% to 30% chance of having a recurrence at some point in the future. Including radiation therapy in the treatment plan after surgery drops the risk of recurrence to about 15%. Learn what additional steps you can take to lower your risk of a new breast cancer diagnosis or a recurrence in the Lower Your Risk section. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive (DCIS again) about half the time and invasive about half the time

Monday, November 19, 2018

Breast Cancer Summit 2019

9th World Congress on Breast cancer and Therapies 5.png
 #Breast cancer #having patient advocates involved helps research team keep the patient in mind in the midst of trying to solve complex biomedical problems.
Patient advocates will review proposals and provide feedback on how the study is likely to impact patients and what the result could be if the drug or treatment approach is ultimately approved.

Thursday, November 15, 2018

Breast Cancer Summit 2019

Inflammatory breast cancer is a rare and very aggressive disease in which cancer cells block lymph vessels in the skin of the breast. This type of breast cancer is called “inflammatory” because the breast often looks swollen and red, or inflamed.
breast-cancer-cells.jpg
Inflammatory breast cancer is rare, accounting for 1 to 5 percent of all breast cancers diagnosed in the United States. Most inflammatory breast cancers are invasive ductal carcinomas, which means they developed from cells that line the milk ducts of the breast and then spread beyond the ducts.
Inflammatory breast cancer progresses rapidly, often in a matter of weeks or months. At diagnosis, inflammatory breast cancer is either stage III or IV disease, depending on whether cancer cells have spread only to nearby lymph nodes or to other tissues as well.
Additional features of inflammatory breast cancer include the following:
  • Compared with other types of breast cancer, inflammatory breast cancer tends to be diagnosed at younger ages.
  • Inflammatory breast cancer is more common and diagnosed at younger ages in African American women than in white women.
  • Inflammatory breast tumors are frequently hormone receptor negative, which means they cannot be treated with hormone therapies, such as tamoxifen, that interfere with the growth of cancer cells fueled by estrogen.
  • Inflammatory breast cancer is more common in obese women than in women of normal weight. 

Wednesday, November 14, 2018

9th World Congress on Breast Cancer and Therapies

HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells.
9th World Congress on Breast Cancer and Therapies (4)
In about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. They're less likely to be sensitive to hormone therapy, though many people with HER2-positive breast cancer can still benefit from hormone therapy.
 
Treatments that specifically target HER2 are very effective. These treatments are so effective that the prognosis for HER2-positive breast cancer is actually quite good.
Treatments include:
  • Ado-trastuzumab emtansine (Kadcyla)
  • Lapatinib (Tykerb)
  • Neratinib (Nerlynx)
  • Pertuzumab (Perjeta)
  • Trastuzumab (Herceptin)

Thursday, November 8, 2018

9th World Congress on Breast Cancer and Therapies

IS BREAST CANCER DIAGNOSIS VIA text message next? A new study finds women with breast cancer are increasingly likely to receive their diagnoses by phone rather than a face-to-face conversation with their doctor.
Is Breast Cancer Diagnosis by Phone OK_
Nearly 60 per cent of women now learns of their breast cancer diagnoses by phone, compared to one-quarter of women in 2007.
Women who received the news over that phone were more likely to have family and friends identified as support members and were somewhat more likely to have localized breast cancer, rather than invasive or spreading cancer. A few women in the study had requested to receive a phone diagnosis.
An earlier study found a mismatch between women's preferences and the reality of how they received their breast cancer diagnoses. Of about 785 breast cancer survivors, only 39 per cent were given the diagnosis face-to-face, although half of the participants would have chosen that method.
For many women in that study, avoiding suspense was important, with more than 80 per cent preferring to receive their cancer biopsy results within two days. However, only 40 per cent of participants found out their results that quickly.

Monday, November 5, 2018

Breast Cancer Summit 2019

The drug combination, arsenic trioxide (Trisenox)and tretinoin (also known as retinoic acid), has essentially turned acute promyelocytic leukaemia (APL) from a fatal disease into a curable one. But the mechanism by which it kills cancer cells has been a mystery.
In an earlier study, Kun Ping Lu, M.D., Ph.D., and Xiao Zhen Zhou, M.D., of Beth Israel Deaconess Medical Center, in Boston, and their colleagues found that retinoic acid inhibits the key enzyme, Pin1. Now, they've found that arsenic also blocks Pin1, and the combination of the two drugs inhibits the enzyme more effectively than either drug aloneBreast Cancer Summit 2019 (14).png

Ductal carcinoma in situ (DCIS) is non-invasive breast cancer . Ductal means that the cancer starts inside the milk ducts, carcinoma refers...